[HTML][HTML] Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
A Younes, AK Gopal, SE Smith, SM Ansell… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
A Younes, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, R Ramchandren…
Journal of clinical oncology, 2012•ncbi.nlm.nih.govPurpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers
monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I
studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile
in patients with relapsed or refractory CD30-positive lymphomas.
monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I
studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile
in patients with relapsed or refractory CD30-positive lymphomas.
Abstract
Purpose
Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas.
ncbi.nlm.nih.gov